References

Management of postmenopausal osteoporosis

10.1210/endrev/bnag006 · 2026 · External reference

Drug therapy for osteoporosis in older adults

10.1016/s0140-6736(21)02646-5 · 2022 · External reference

Skeletal aging

10.1016/j.mayocp.2022.03.011 · 2022 · External reference

Bone aging, cellular senescence, and osteoporosis

10.1002/jbm4.10488 · 2021 · External reference

The clinician's guide to prevention and treatment of osteoporosis

10.1007/s00198-021-05900-y · 2022 · External reference

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

10.1007/s00198-019-05176-3 · 2020 · External reference

Clinical practice. Postmenopausal osteoporosis

10.1056/nejmcp1513724 · 2016 · External reference

Imminent risk of fracture after fracture

10.1007/s00198-016-3868-0 · 2017 · External reference

Bone quality--the material and structural basis of bone strength and fragility

10.1056/nejmra053077 · 2006 · External reference

Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024

10.1093/jbmr/zjae119 · 2024 · External reference

Management of patients at very high risk of osteoporotic fractures through sequential treatments

10.1007/s40520-022-02100-4 · 2022 · External reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group

10.1016/s0140-6736(96)07088-2 · 1996 · External reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

10.1056/nejmoa067312 · 2007 · External reference

Fracture prevention with zoledronate in older women with osteopenia

10.1056/nejmoa1808082 · 2018 · External reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

10.1056/nejmoa0809493 · 2009 · External reference

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

10.1016/s2213-8587(17)30138-9 · 2017 · External reference

Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension

10.1002/jbmr.3337 · 2018 · External reference

Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses

10.1002/jbmr.4705 · 2022 · External reference

Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS

10.1016/j.bone.2017.08.003 · 2017 · External reference

Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases

10.1002/jbmr.3110 · 2017 · External reference

Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline

10.1210/jc.2019-00221 · 2019 · External reference

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research

10.1002/jbmr.1998 · 2014 · External reference

Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update

10.1210/clinem/dgaa048 · 2020 · External reference

AMERICAN association of clinical endocrinologists/AMERICAN COLLEGE OF endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal OSTEOPOROSIS-2020 update

10.4158/gl-2020-0524suppl · 2020 · External reference

Identification of senescent cells in the bone microenvironment

10.1002/jbmr.2892 · 2016 · External reference

Targeting cellular senescence prevents age-related bone loss in mice

10.1038/nm.4385 · 2017 · External reference

Cellular senescence and the skeleton: pathophysiology and therapeutic implications

10.1172/jci154888 · 2022 · External reference

Inhibiting cellular senescence: a new therapeutic paradigm for age-related osteoporosis

10.1210/jc.2017-02694 · 2018 · External reference

Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial

10.1038/s41591-024-03096-2 · 2024 · External reference

Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes

10.1172/jci.insight.135236 · 2020 · External reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

10.1056/nejm200105103441904 · 2001 · External reference

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis

10.1359/jbmr.2003.18.1.9 · 2003 · External reference

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

10.1056/nejmoa071408 · 2007 · External reference

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

10.1016/s0140-6736(17)32137-2 · 2018 · External reference

Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial

10.1001/jama.2016.11136 · 2016 · External reference

ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis

10.1210/jc.2018-00163 · 2018 · External reference

Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis

10.1002/jbmr.3051 · 2017 · External reference

Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension study): a randomized controlled trial

10.1210/jc.2013-4440 · 2014 · External reference

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial

10.1016/s0140-6736(15)61120-5 · 2015 · External reference

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

10.1093/hmg/10.5.537 · 2001 · External reference

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

10.1086/318811 · 2001 · External reference

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

10.1016/s0092-8674(01)00571-2 · 2001 · External reference

High bone density due to a mutation in LDL-receptor-related protein 5

10.1056/nejmoa013444 · 2002 · External reference

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

10.1093/emboj/cdg599 · 2003 · External reference

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

10.1084/jem.20031454 · 2004 · External reference

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

10.1074/jbc.m413274200 · 2005 · External reference

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

10.1074/jbc.m504308200 · 2005 · External reference

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin

10.1074/jbc.m705092200 · 2008 · External reference

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

10.1359/jbmr.081206 · 2009 · External reference

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study

10.1002/jcph.239 · 2014 · External reference

Romosozumab in postmenopausal women with low bone mineral density

10.1056/nejmoa1305224 · 2014 · External reference

Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment

10.1002/jbmr.3735 · 2019 · External reference

Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial

10.1002/jbmr.4457 · 2022 · External reference

Romosozumab treatment in postmenopausal women with osteoporosis

10.1056/nejmoa1607948 · 2016 · External reference

One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study

10.1002/jbmr.3622 · 2019 · External reference

Romosozumab or alendronate for fracture prevention in women with osteoporosis

10.1056/nejmoa1708322 · 2017 · External reference

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

10.1007/s00198-024-07049-w · 2024 · External reference

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

10.1016/s0140-6736(17)31613-6 · 2017 · External reference

Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids

10.1074/jbc.m702810200 · 2007 · External reference

Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes

10.1172/jci195772 · 2026 · External reference

Deconstructing senescence phenotypes in cells of the bone and bone marrow

10.1172/jci204645 · 2026 · External reference

Determinants of bone strength and quality in diabetes mellitus in humans

10.1016/j.bone.2015.07.027 · 2016 · External reference

Type 2 diabetes and the skeleton: new insights into sweet bones

10.1016/s2213-8587(15)00283-1 · 2016 · External reference

Type 2 diabetes mellitus and bone

10.1111/joim.12725 · 2018 · External reference

Mechanisms of diabetes mellitus-induced bone fragility

10.1038/nrendo.2016.153 · 2017 · External reference

Older women with diabetes have an increased risk of fracture: a prospective study

10.1210/jcem.86.1.7139 · 2001 · External reference

Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis

10.1007/s00198-006-0253-4 · 2007 · External reference

Type 2 diabetes and fracture risk in older women

10.1001/jamanetworkopen.2024.25106 · 2024 · External reference

The serial cultivation of human diploid cell strains

10.1016/0014-4827(61)90192-6 · 1961 · External reference

Cellular senescence: defining a path forward

10.1016/j.cell.2019.10.005 · 2019 · External reference

Cellular senescence: a key therapeutic target in aging and diseases

10.1172/jci158450 · 2022 · External reference

Aging, cellular senescence, and cancer

10.1146/annurev-physiol-030212-183653 · 2013 · External reference

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

10.1371/journal.pbio.0060301 · 2008 · External reference

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion

10.1038/ncb1909 · 2009 · External reference

Hallmarks of aging: an expanding universe

10.1016/j.cell.2022.11.001 · 2023 · External reference

Cellular senescence and the senescent secretory phenotype: therapeutic opportunities

10.1172/jci64098 · 2013 · External reference

Cellular senescence in bone

10.1016/j.bone.2019.01.015 · 2019 · External reference

The role of cellular senescence in ageing and endocrine disease

10.1038/s41574-020-0335-y · 2020 · External reference

The osteocyte: new insights

10.1146/annurev-physiol-021119-034332 · 2020 · External reference

Local senolysis in aged mice only partially replicates the benefits of systemic senolysis

10.1172/jci162519 · 2023 · External reference

Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair

10.1172/jci179834 · 2024 · External reference

Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity

10.1111/acel.13602 · 2022 · External reference

Targeted reduction of senescent cell burden alleviates focal radiotherapy-related bone loss

10.1002/jbmr.3978 · 2020 · External reference

Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus quercetin in individuals with diabetic kidney disease

10.1016/j.ebiom.2019.08.069 · 2019 · External reference

Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study

10.1016/j.ebiom.2018.12.052 · 2019 · External reference

Characterization of human senescent cell biomarkers for clinical trials

10.1111/acel.14489 · 2025 · External reference

Senolytic drugs: from discovery to translation

10.1111/joim.13141 · 2020 · External reference

Senolytics improve physical function and increase lifespan in old age

10.1038/s41591-018-0092-9 · 2018 · External reference

FRAX and the assessment of fracture probability in men and women from the UK

10.1007/s00198-007-0543-5 · 2008 · External reference

Estrogen and the skeleton

10.1016/j.tem.2012.03.008 · 2012 · External reference

The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?

10.1002/jbmr.262 · 2011 · External reference

Unresolved reference

2019 · External reference

Romosozumab versus alendronate and fracture risk in women with osteoporosis

2018 · External reference

The Achilles' heel of senescent cells: from transcriptome to senolytic drugs

10.1111/acel.12344 · 2015 · External reference